Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer

Gynecologic Oncology

Volumn 72, Issue 2, 1999, Pages 148-153

  Burger, Robert A ^a   DiSaia, Philip J ^a   Roberts, James A ^b   O'Rourke, Mark ^c   Gershenson, David M ^d   Homesley, Howard D ^e   Lichtman, Stuart M ^f   Barnes, Willard ^g   Moore, David H ^h   Monk, Bradley J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c GREENVILLE HOSPITAL SYSTEM   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; NAVELBINE; PACLITAXEL; PLATINUM;

ADULT; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM TUMOR; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; NEUROTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032936206     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5243     Document Type: Article

References (25)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 45:8-30, 1995
2. DiSaia PJ, Creasman WT: Epithelial Ovarian Cancer, in DiSaia PJ, Creasman WT (eds): Clinical Gynecologic Oncology. St. Louis, MO, Mosby Year Book, 1993, pp 333-425
3. Cros S, Wright M, Morimoto M, Lataste H, Couzinier JP, Krikorian A: Experimental antitumor activity of Navelbine. Semin Oncol 16:15-20, 1989
4. Besenval M, Delgado M, Demarez JP, Krikorian A: Safety and tolerance of Navelbine in phase I-II clinical studies. Semin Oncol 16:37-40, 1989
5. Budman DR: Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest 15:475-490, 1997
6. Potier P: The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 16:2-4, 1989
7. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993
8. Cvitkovic E, Izzo J: The current and future place of vinorelbine in cancer therapy. Drugs 44(Suppl 4):36-45, 1992
9. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC: Efficacy of Navelbine (NVB) in non-small-cell lung cancer (NSCLC). Semin Oncol 16:26-29, 1989
10. Johnson SA, Harper P, Hortobagyi GN, Pouillart P: Vinorelbine: an overview. Cancer Treat Rev 22:127-142, 1996
11. George MJ, Heron JF, Kerbrat P, Chauvergne J, Goupil A, Lebrun D, Guastalla JP, Namer M, Bugat R, Ayme Y: Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers. Semin Oncol 16:30-32, 1989
12. Bajetta E, Di Leo A, Biganzoli L, Mariani L, Cappuzzo F, Di Bartolomeo M, Zilembo N, Artale S, Magnani E, Celio L, Buzzoni R, Carnaghi C: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 14:2546-2551, 1996
13. Mathe G, Reizenstein P: Phase I pharmacologic study of a new Vinca alkaloid: Navelbine. Cancer Lett 27:285-293, 1985
14. Ozols RF: Future directions in the chemotherapy of ovarian cancer. Semin Oncol 24(5 Suppl 15):S15-86-S15-90, 1997
15. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
16. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, ten Bokkel Huinink WW: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996
17. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
18. Lund B, Hansen OP, Neijt JP, Theilade K, Hansen M: Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anti-Cancer Drugs 6(Suppl 6):61-62, 1995
19. Rose PG, Blessing JA, Mayer AR, Homesley HD: Prolonged oral etoposide as second line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16:405-410, 1998
20. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997
21. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
22. Gebbia V, Caruso M, Valenza R, Testa A, Cannata G, Verderame F, Cipolla C, Curto G, Oliveri D, Chiarenza M, et al.: Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non-small-cell lung carcinoma. Anticancer Res 14:1247-1249, 1994
23. Bretti S, Berruti A, Gorzegno G, La Ciura P, Paze E, Celano A, Grecchi G, Perroni D, Bumma C, Dogliotti L: Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small-cell lung cancer patients. Lung Cancer 14:353-360, 1996
24. Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J, et al.: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small-cell lung cancer: a randomized trial. Ann Oncol 5:37-42, 1994
25. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riverie A, Lianes P, Chomy P, Cigolari S, et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994